Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab and Tuvonralimab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06932068
What this trial is testing

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Who this might be right for
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 77
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07349225
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Who this might be right for
ES-SCLC
The Second Affiliated Hospital of Dalian Medical University 46
Testing effectiveness (Phase 2)Looking for participantsNCT06911684
What this trial is testing

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Who this might be right for
Rectal Cancer Patients
Sun Yat-sen University 88
Testing effectiveness (Phase 2)Looking for participantsNCT06941766
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Who this might be right for
Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007728
What this trial is testing

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Who this might be right for
Colorectal NeoplasmsSecondary Malignant Neoplasm of Liver
Peking University Cancer Hospital & Institute 54
Testing effectiveness (Phase 2)Looking for participantsNCT07646301
What this trial is testing

Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Who this might be right for
Uterine Cervical NeoplasmsLocally Advanced
Sun Yat-sen University 103
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06986057
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer

Who this might be right for
Cervical CancerNeoadjuvant Therapy
Shandong Tumor Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07400315
What this trial is testing

First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 64
Not applicableNot Yet RecruitingNCT07187674
What this trial is testing

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Who this might be right for
Triple Negative Breast Cancer (TNBC)
Harbin Medical University 20
Testing effectiveness (Phase 2)Looking for participantsNCT07099274
What this trial is testing

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

Who this might be right for
HCC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06958484
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence

Who this might be right for
HCC - Hepatocellular CarcinomaAdjuvant Treatment
The Affiliated Hospital of Xuzhou Medical University 60
Testing effectiveness (Phase 2)Looking for participantsNCT07776080
What this trial is testing

Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Who this might be right for
HCC - Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 35
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07129161
What this trial is testing

Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Sun Yat-sen University 66
Not applicableNot Yet RecruitingNCT07652983
What this trial is testing

TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Qilu Hospital of Shandong University 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07172217
What this trial is testing

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

Who this might be right for
Recurrent Cervical Cancer
Qilu Hospital of Shandong University 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07502014
What this trial is testing

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer (CRC)mCRC
Huazhong University of Science and Technology 60
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Testing effectiveness (Phase 2)Looking for participantsNCT07232654
What this trial is testing

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Who this might be right for
LOCALLY ADVANCED CERVICAL CANCERS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128251
What this trial is testing

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular Carcinoma (HCC)ImmunotherapyPD-1+2 more
Anhui Provincial Hospital 47